ATA168099A - Pharmazeutische zusammensetzung enthaltend ein antigen - Google Patents

Pharmazeutische zusammensetzung enthaltend ein antigen

Info

Publication number
ATA168099A
ATA168099A AT0168099A AT168099A ATA168099A AT A168099 A ATA168099 A AT A168099A AT 0168099 A AT0168099 A AT 0168099A AT 168099 A AT168099 A AT 168099A AT A168099 A ATA168099 A AT A168099A
Authority
AT
Austria
Prior art keywords
antig
pharmaceutical composition
composition containing
pharmaceutical
composition
Prior art date
Application number
AT0168099A
Other languages
English (en)
Other versions
AT408721B (de
Inventor
Julia-Kristina Mag Fleitmann
Frank Dr Mattner
Michael Dr Buschle
Jack Dr Melling
Original Assignee
Cistem Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cistem Biotechnologies Gmbh filed Critical Cistem Biotechnologies Gmbh
Priority to AT0168099A priority Critical patent/AT408721B/de
Priority to PE2000001035A priority patent/PE20010704A1/es
Priority to DE60029115T priority patent/DE60029115T2/de
Priority to EP06101092A priority patent/EP1745798A3/de
Priority to PCT/EP2000/009657 priority patent/WO2001024822A2/en
Priority to EP10179382A priority patent/EP2269640A3/de
Priority to AU79121/00A priority patent/AU7912100A/en
Priority to EP10179393A priority patent/EP2269643A3/de
Priority to AT00969387T priority patent/ATE331529T1/de
Priority to EP00969387A priority patent/EP1218031B1/de
Priority to EP10179390A priority patent/EP2269642A3/de
Priority to ARP000105196A priority patent/AR025937A1/es
Priority to EP10179386A priority patent/EP2269641A3/de
Publication of ATA168099A publication Critical patent/ATA168099A/de
Application granted granted Critical
Publication of AT408721B publication Critical patent/AT408721B/de
Priority to US10/114,823 priority patent/US20030099663A1/en
Priority to US11/082,595 priority patent/US20050163797A1/en
Priority to US12/248,744 priority patent/US20090130135A1/en
Priority to US12/248,397 priority patent/US20090104217A1/en
Priority to US13/110,454 priority patent/US8277815B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT0168099A 1999-10-01 1999-10-01 Pharmazeutische zusammensetzung enthaltend ein antigen AT408721B (de)

Priority Applications (18)

Application Number Priority Date Filing Date Title
AT0168099A AT408721B (de) 1999-10-01 1999-10-01 Pharmazeutische zusammensetzung enthaltend ein antigen
PE2000001035A PE20010704A1 (es) 1999-10-01 2000-09-29 Composicion farmaceutica que comprende un antigeno
ARP000105196A AR025937A1 (es) 1999-10-01 2000-10-02 Composicion farmaceutica que comprende un antigeno, un inmunoestimulante y un adyuvante policationico.
PCT/EP2000/009657 WO2001024822A2 (en) 1999-10-01 2000-10-02 Pharmaceutical composition comprising an antigen
EP10179382A EP2269640A3 (de) 1999-10-01 2000-10-02 Hcv Vakzine-Zusammensetzungen
AU79121/00A AU7912100A (en) 1999-10-01 2000-10-02 Pharmaceutical composition comprising an antigen
EP10179393A EP2269643A3 (de) 1999-10-01 2000-10-02 Hcv Vakzine-Zusammensetzungen
AT00969387T ATE331529T1 (de) 1999-10-01 2000-10-02 Antigen enthaltende pharmazeutische zusammensetzung
DE60029115T DE60029115T2 (de) 1999-10-01 2000-10-02 Antigen enthaltende pharmazeutische zusammensetzung
EP10179390A EP2269642A3 (de) 1999-10-01 2000-10-02 Hcv Vakzine-Zusammensetzungen
EP06101092A EP1745798A3 (de) 1999-10-01 2000-10-02 Hcv vakzine-zusammensetzungen
EP10179386A EP2269641A3 (de) 1999-10-01 2000-10-02 Hcv Vakzine-Zusammensetzungen
EP00969387A EP1218031B1 (de) 1999-10-01 2000-10-02 Antigen enthaltende pharmazeutische zusammensetzung
US10/114,823 US20030099663A1 (en) 1999-10-01 2002-04-01 Pharmaceutical composition comprising an antigen
US11/082,595 US20050163797A1 (en) 1999-10-01 2005-03-17 Pharmaceutical composition comprising an antigen
US12/248,744 US20090130135A1 (en) 1999-10-01 2008-10-09 Hcv vaccines
US12/248,397 US20090104217A1 (en) 1999-10-01 2008-10-09 Pharmaceutical Composition Comprising An Antigen
US13/110,454 US8277815B2 (en) 1999-10-01 2011-05-18 Pharmaceutical composition comprising an antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0168099A AT408721B (de) 1999-10-01 1999-10-01 Pharmazeutische zusammensetzung enthaltend ein antigen

Publications (2)

Publication Number Publication Date
ATA168099A true ATA168099A (de) 2001-07-15
AT408721B AT408721B (de) 2002-02-25

Family

ID=3518675

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0168099A AT408721B (de) 1999-10-01 1999-10-01 Pharmazeutische zusammensetzung enthaltend ein antigen
AT00969387T ATE331529T1 (de) 1999-10-01 2000-10-02 Antigen enthaltende pharmazeutische zusammensetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00969387T ATE331529T1 (de) 1999-10-01 2000-10-02 Antigen enthaltende pharmazeutische zusammensetzung

Country Status (8)

Country Link
US (4) US20030099663A1 (de)
EP (6) EP2269643A3 (de)
AR (1) AR025937A1 (de)
AT (2) AT408721B (de)
AU (1) AU7912100A (de)
DE (1) DE60029115T2 (de)
PE (1) PE20010704A1 (de)
WO (1) WO2001024822A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
JP2004517609A (ja) * 2000-09-01 2004-06-17 エピミューン インコーポレイテッド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの用途
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
WO2002053184A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Uses for polycationic compounds as vaccine adjuvants
EP1347775B1 (de) 2001-01-05 2016-11-30 Valneva Austria GmbH Gebrauch von polykationischen substanzen als adjuvantien für impfstoffe
US20040081655A1 (en) * 2001-01-05 2004-04-29 Karen Lingnau Methods and compositions comprising polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1390494A2 (de) * 2001-05-21 2004-02-25 Intercell AG Verfahren zur stabilisierung von nukleinsäuren
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
EP1537418A2 (de) 2002-09-13 2005-06-08 Intercell AG Verfahren zur isolierung von hepatitis c virus peptiden
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
DK1581251T3 (da) 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
CN1756843B (zh) 2003-03-04 2012-03-21 英特塞尔股份公司 化脓链球菌抗原
AU2004224746B2 (en) 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
AU2004226262A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
EP1620460A2 (de) 2003-05-07 2006-02-01 Intercell AG Streptococcus agalactiae-antigene i + ii
EP1629005A2 (de) 2003-05-30 2006-03-01 Intercell AG Antigene aus enterococcus
CA2530062A1 (en) * 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
EP1722819B1 (de) 2004-03-12 2007-12-26 Intercell AG Verfahren zur solubilisierung von peptid-mischungen
US20050208482A1 (en) * 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
EP2149583B1 (de) 2004-09-24 2015-10-28 Novartis AG Modifiziertes VP1-Capsid Protein von Parvovirus B19
WO2006045677A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
EP1976551A4 (de) * 2005-12-23 2009-12-30 Altus Pharmaceuticals Inc Zusammensetzungen mit polykation-komplex-proteinkristallen und behandlungsverfahren damit
CA2645832A1 (en) * 2006-04-25 2007-11-01 Intercell Ag Hcv vaccinations
EP2292647A3 (de) 2006-07-07 2011-06-08 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
EP2289906A1 (de) 2006-09-15 2011-03-02 Intercell AG Borrelia-Antigene
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
EP2266592A3 (de) 2007-01-12 2012-08-08 Intercell AG Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
EP2511291A3 (de) 2007-06-18 2012-11-07 Intercell AG Chlamydia-Antigene
WO2009046872A2 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
AU2009226949A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
WO2009129498A2 (en) * 2008-04-17 2009-10-22 Immuneregen Biosciences, Inc. Substance p and analogs thereof as a cancer immunogenic composition adjuvant
EP2424882A2 (de) 2009-02-05 2012-03-07 Intercell AG Gegen e.-faecalis schützende peptide, verfahren und anwendungen, die damit in zusammenhang stehen
EP2405938A2 (de) 2009-02-13 2012-01-18 Intercell AG Nicht typisierbare haemophilus influenza-antigene
JP5692933B2 (ja) 2009-03-23 2015-04-01 ナニアールエックス セラピューティックス インコーポレイテッド 免疫刺激ＨＩＶＴａｔ誘導体ポリペプチドによる腫瘍治療
US8321012B2 (en) 2009-12-22 2012-11-27 The Invention Science Fund I, Llc Device, method, and system for neural modulation as vaccine adjuvant in a vertebrate subject
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
EP2446898A1 (de) * 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Verwendung von Wachstumshormonen zur Verbesserung der Immunantwort bei immunsupprimierten Patienten
ES2728653T3 (es) * 2011-05-18 2019-10-28 Matrivax Inc Composiciones vacunales con una matriz proteica que incluye policationes
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
US10398772B2 (en) 2014-01-08 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
US10816554B2 (en) 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
US12274731B1 (en) 2018-07-12 2025-04-15 Washington University Polybasic antimalarial agents and methods of use thereof
KR20220010478A (ko) 2019-05-20 2022-01-25 발네바 에스이 기도 감염의 치료 또는 예방용 서브유닛 백신
WO2020240268A1 (en) 2019-05-31 2020-12-03 Universidad De Chile An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
KR20230167017A (ko) 2021-04-09 2023-12-07 발네바 에스이 인간 메타뉴모 바이러스 백신
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1290141A (de) * 1968-05-31 1972-09-20
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US4777245A (en) * 1984-01-06 1988-10-11 Genelabs Incorporated Non-human primate monoclonal antibodies and methods
EP0211601A3 (de) 1985-07-30 1988-01-13 International Minerals And Chemical Corporation Stabilisierung von Wachstumshormonen
US4837202A (en) 1987-09-14 1989-06-06 Pitman-Moore, Inc. Method for stimulating the immune system
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
GB8821656D0 (en) 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
DE3834729A1 (de) * 1988-10-12 1990-04-19 Behringwerke Ag Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8921470D0 (en) * 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
FR2658895B1 (fr) 1990-02-27 1992-07-03 Hydraulique Meca Ste Nle Gle Robinet-vanne.
GB9010058D0 (en) * 1990-05-04 1990-06-27 Health Lab Service Board Method and composition for the treatment of cancer
US6172189B1 (en) * 1990-08-24 2001-01-09 Abbott Laboratories Hepatitis C assay utilizing recombinant antigens
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
US5202119A (en) 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
US20030152580A1 (en) * 1994-07-21 2003-08-14 Alessandro Sette Hla binding peptides and their uses
JPH06199894A (ja) * 1992-08-27 1994-07-19 Asahi Chem Ind Co Ltd Ｃ型肝炎ウイルスのコア蛋白質領域に存在するｔ細胞エピトープ
EP0587958A1 (de) 1992-09-14 1994-03-23 Fabriques De Tabac Reunies S.A. Verfahren und vorrichtung zur Regulierung der Geschwindigkeit eines Produktes in einer Leitung und Zigarettenherstellungsmaschine mit einer solchen Vorrichtung
WO1994015634A1 (en) * 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
FR2708855B1 (fr) * 1993-08-13 1995-10-13 Dolisos Lab Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes.
US5830877A (en) 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
ES2197170T3 (es) * 1993-11-04 2004-01-01 Innogenetics N.V. Epitopos de celulas t humanas inmunologicamente dominantes del virus de la hepatitis c.
DE69517521T2 (de) * 1994-04-08 2001-03-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
EP0863913A4 (de) * 1995-08-21 2001-04-11 Univ Duke Methode zur erhölung der dichte eines antigens auf antigen-präsentierenden zellen
ATE455171T1 (de) 1995-09-21 2010-01-15 Genentech Inc Varianten des menschlichen wachstumshormons
AUPN801296A0 (en) * 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
CA2289040A1 (en) * 1997-05-01 1998-11-05 Protechtion Unlimited, Inc. Nerve growth factor as a vaccine adjuvant
ES2265165T3 (es) * 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
AUPP060097A0 (en) 1997-11-28 1998-01-08 Commonwealth Scientific And Industrial Research Organisation Adjuvant system for enhanced response
US6072889A (en) 1997-12-03 2000-06-06 The Raytheon Company Method and system for imaging target detection
AU5776799A (en) * 1998-08-21 2000-03-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Modified hcv peptide vaccines
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
JP2003509465A (ja) * 1999-07-19 2003-03-11 エピミューン， インコーポレイテッド ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
EP1195381A1 (de) * 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
CA2530062A1 (en) 2003-07-11 2005-01-20 Intercell Ag Hcv vaccines
WO2006045677A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients

Also Published As

Publication number Publication date
US20110300169A1 (en) 2011-12-08
EP2269642A2 (de) 2011-01-05
AR025937A1 (es) 2002-12-18
EP1218031A2 (de) 2002-07-03
US20050163797A1 (en) 2005-07-28
DE60029115T2 (de) 2007-06-14
DE60029115D1 (de) 2006-08-10
EP1745798A2 (de) 2007-01-24
EP2269640A2 (de) 2011-01-05
US20090104217A1 (en) 2009-04-23
EP2269643A3 (de) 2011-05-04
EP2269641A3 (de) 2011-05-04
US8277815B2 (en) 2012-10-02
WO2001024822A2 (en) 2001-04-12
EP2269643A2 (de) 2011-01-05
EP2269641A2 (de) 2011-01-05
US20030099663A1 (en) 2003-05-29
EP1745798A3 (de) 2007-03-07
WO2001024822A3 (en) 2001-12-20
AU7912100A (en) 2001-05-10
EP2269642A3 (de) 2011-05-04
EP2269640A3 (de) 2011-05-04
PE20010704A1 (es) 2001-07-11
EP1218031B1 (de) 2006-06-28
ATE331529T1 (de) 2006-07-15
AT408721B (de) 2002-02-25

Similar Documents

Publication Publication Date Title
ATE331529T1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
ATE355271T1 (de) Pharmazeutische zusammensetzung
DE69812089D1 (de) Pharmazeutische omeprazol-formulierung
DE69726015D1 (de) Pharmazeutische zusammensetzung enthaltend koenzym q-10
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
NO20015175D0 (no) Farmasöytisk sammensetning
ATE320244T1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
ATE238812T1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
EE200000383A (et) Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
DE59915033D1 (de) Pharmazeutische Zubereitung
ATE490327T1 (de) Impfstoffzusammensetzung
DE60315939D1 (de) Pharmazeutische zusammensetzung enthaltend ein androgen
DZ3219A1 (fr) Vaccin
DE60129238D1 (de) Pharmazeutische zusammensetzung
ATE350016T1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
DE59801987D1 (de) Pharmazeutische zusammensetzung enthaltend peptichemio
DE10084344T1 (de) Cyclosporin enthaltende pharmazeutische Zusammensetzung
DE69614407D1 (de) Pharmazeutische zusammensetzungen
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
ATE412405T1 (de) Pharmazeutische zusammensetzung mit modifiziertem träger
AR025867A1 (es) Formulacion portasdora farmaceutica
FI4488U1 (fi) Farmaseuttinen koostumus
EP1124557A4 (de) Pharmazeutische zusammensetzung
EP1051141A4 (de) Insulin haltige pharmazeutische zusammensetzungen enthaltend einen amylinagonisten

Legal Events

Date Code Title Description
PC Change of the owner

Owner name: INTERCELL AG, AT

Effective date: 20120919

MM01 Lapse because of not paying annual fees

Effective date: 20130715